Epsilon M&A Deal Report - TransCure bioServices
Transaction Multiples for the Valuation of Private Companies
Private group led by Cathay Capital / TransCure bioServices
No EMAT :
120428
Announced Date :
29/06/2022
Type :
Acquisition of Minority Stake
Deal Value :
Yes
Acquirer :
Private group led by Cathay Capital
Target :
TransCure bioServices
Country :
Haute-Savoie
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Founded in 2012, TransCure bioServices is a “one-stop-shop” preclinical contract research organization (CRO). > Specializing in advanced preclinical in vivo pharmacology with mouse models of fully...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
||||||
| Current |
|
|
ns | ns | ns | ns |
Rating :
***
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 37
| Date | Acquirer | Target | Country | Multiples | See details |
| 10/10/2023 | Etap | Syncrosome | Bouches-Du-Rhône | *** | 120415 |
| 23/12/2024 | Private Group led by Andera Acto | Centre Azuréen de Cancérologie (CAC) | Alpes-Maritimes | * | 120397 |
Source: Epsilon Research / EMAT
